|1.||Graf, Ana: 1 article (08/2006)|
|2.||Sindrup, Søren H: 1 article (08/2006)|
|3.||Sfikas, Nikolaos: 1 article (08/2006)|
08/01/2006 - "There was no significant difference between TKA731 and placebo in change in pain rating from baseline to study end neither for rating of total pain (mean -13.4 mm vs. -11.6 mm, p = 0.664) nor for change in ratings of different pain symptoms (touch- or pressure-evoked pain, pain paroxysms, steady burning or deep aching pain) (p = 0.169-0.834)."
|2.||Diabetic Neuropathies (Diabetic Neuropathy)
08/01/2006 - "The aim of this multicenter, randomised, double-blind, placebo-controlled and parallel-group study was to test if the non-peptide NK(1)-receptor antagonist TKA731 would relieve painful diabetic polyneuropathy. "
08/01/2006 - "The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trial."